Assessment of the treatment effects of exacerbation of hemorrhoidal disease using Distreptaza® 2.0 g suppositories in combination with phlebotropic and locally soothing treatment.
A prospective, open study.
Hemorrhoidal disease is the most common proctological disease in the adult population, but despite this, the description of symptoms in the anal area remains embarrassing for many people. This results in a late diagnosis and a significant prolongation of the treatment period. Hemorrhoidal disease develops in stages and can have various clinical pictures, with the incidence increasing with age. Importantly, conservative management can reduce or completely eliminate symptoms in the early stages of the disease.
In connection with the above and with the utmost concern for the patient's well-being, we invite you to participate in the study entitled: "Assessment of the treatment effects of exacerbation of hemorrhoidal disease using Distreptaza® 2.0 g suppositories in combination with phlebotropic and locally soothing treatment."
Your active participation is crucial for the success of the study and to indicate the therapeutic direction of hemorrhoidal disease. The diagnostic procedures used, and the collected data will allow for the preparation of a report and presentation of the results.
Stages of the study:
Registration and acceptance of the online agreement (the agreement will be sent to the email address provided during registration).
Patient observation and data registration in the eCRF system.
Final report and presentation of the study results.